Scholarlink

Objectives <p>This study aims to build a prediction model based on MRI features and clinical characteristics for early tumor recurrence (&lt; 12 months) in lesions which evaluated as LR-TR nonviable at first follow up (1–2 months) after transaterial chemoembolization (TACE).</p> Methods <p>This multicenter retrospective study included consecutive patients with hepatocellular carcinoma (HCC) who underwent initial TACE from five centers between February 2015 and October 2022. Additionally, patients from a completed clinical trial (NCT03113955) were also included for this retrospective analysis. Nineteen baseline imaging features and six first follow-up imaging features were evaluated for lesions classified as LR-TR nonviable at the first post-TACE imaging assessment. A predictive model integrating clinical and MRI features for early recurrence of LR-TR nonviable lesions was developed with logistic regression analyses and validated on a 5-fold cross-validation. The model’s performance was further validated by analyzing relapse-free survival (RFS) using Kaplan-Meier curves.</p> Results <p>Non-smooth margin (OR: 4.69; 95% CI: 1.91, 11.56; <i>P</i> = 0.001) and peritumoral hyperintensity on T2-weighted imaging or diffusion-weighted imaging (OR: 6.12; 95% CI: 2.53, 14.80; <i>P</i> &lt; 0.001) were identified as independent risk factors for early recurrence of LR-TR nonviable lesions. The non-Viable Recurrence (nVR) model, developed using these two features, achieved area under the receiver operating characteristic curve of 0.759 (0.734, 0.784) in the training cohort and 0.765 (0.632, 0.898) in the validation cohort. Patients were stratified into high-risk and low-risk groups based on the Youden index, with RFS significantly differing between these groups in both the training (<i>P</i> &lt; 0.001) and validation cohorts (<i>P</i> = 0.009).</p> Conclusion <p>Based on two radiologic features, the nVR model has demonstrated relatively reliable efficacy in predicting early post-TACE recurrence.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The nVR model: prediction of LI-RADS treatment response nonviable recurrence of hepatocellular carcinoma after primary transarterial chemoembolization

  • 期刊论文

  • 发表日期：

    2025年4月11日

查看全文
  • Shuhang Zhang,
  • Weilang Wang,
  • Xiuming Zhang,
  • Binyan Zhong,
  • Feng Feng,
  • Wu Cai,
  • Binrong Li,
  • Varsha Ajith Menon,
  • Shuwei Zhou,
  • Teng Zhang,
  • Xunjun Chen,
  • Shenghong Ju,
  • Yuan-Cheng Wang

摘要

Objectives

This study aims to build a prediction model based on MRI features and clinical characteristics for early tumor recurrence (< 12 months) in lesions which evaluated as LR-TR nonviable at first follow up (1–2 months) after transaterial chemoembolization (TACE).

Methods

This multicenter retrospective study included consecutive patients with hepatocellular carcinoma (HCC) who underwent initial TACE from five centers between February 2015 and October 2022. Additionally, patients from a completed clinical trial (NCT03113955) were also included for this retrospective analysis. Nineteen baseline imaging features and six first follow-up imaging features were evaluated for lesions classified as LR-TR nonviable at the first post-TACE imaging assessment. A predictive model integrating clinical and MRI features for early recurrence of LR-TR nonviable lesions was developed with logistic regression analyses and validated on a 5-fold cross-validation. The model’s performance was further validated by analyzing relapse-free survival (RFS) using Kaplan-Meier curves.

Results

Non-smooth margin (OR: 4.69; 95% CI: 1.91, 11.56; P = 0.001) and peritumoral hyperintensity on T2-weighted imaging or diffusion-weighted imaging (OR: 6.12; 95% CI: 2.53, 14.80; P < 0.001) were identified as independent risk factors for early recurrence of LR-TR nonviable lesions. The non-Viable Recurrence (nVR) model, developed using these two features, achieved area under the receiver operating characteristic curve of 0.759 (0.734, 0.784) in the training cohort and 0.765 (0.632, 0.898) in the validation cohort. Patients were stratified into high-risk and low-risk groups based on the Youden index, with RFS significantly differing between these groups in both the training (P < 0.001) and validation cohorts (P = 0.009).

Conclusion

Based on two radiologic features, the nVR model has demonstrated relatively reliable efficacy in predicting early post-TACE recurrence.

Graphical abstract